Scarica l'app Stockscreener
6.92
0.29%
-0.02
Dopo l'orario di chiusura:
6.88
-0.04
-0.58%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Savara Inc Borsa (SVRA) Ultime notizie
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI - BioSpace
Savara (SVRA) Is Up 8.9% After European Patent Boost For MOLBREEVI Nebulized Therapy - simplywall.st
Savara (SVRA) Deepens Patent Moat for MOLBREEVI in Europe Is Its Rare-Disease Edge Widening? - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Savara Inc. (SVRA) And Encourages Shareholders to Connect - ACCESS Newswire
Savara to Get Patent for Liquid Formulation of Lung Disease Therapy from European Patent Office - marketscreener.com
Savara announces EPO intention to grant Molbreevi patent application - TipRanks
Savara (SVRA) Receives Positive Patent News from European Office - GuruFocus
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* - Yahoo Finance
Savara (NASDAQ:SVRA) Reaches New 12-Month HighHere's What Happened - MarketBeat
Savara stock hits 52-week high at 6.61 USD By Investing.com - Investing.com Canada
Certain Options of Savara Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Certain Warrants of Savara Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Certain Pre-Funded Warrants of Savara Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
172,836,922 Common Stock of Savara Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Savara stock hits 52-week high at 6.61 USD - Investing.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Savara Inc. (SVRA) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Savara (NASDAQ:SVRA) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Affinity Asset Advisors LLC Purchases New Stake in Savara Inc. $SVRA - MarketBeat
Savara issues patent for Molbreevi from European Patent Office - MSN
Savara rumor highlighted in Betaville blog - MSN
How strong dollar benefits Savara Inc. (YB4P) stock2025 Market WrapUp & Low Drawdown Investment Ideas - Newser
Dir Elam Acquires 4,387 Of Savara Inc [SVRA] - TradingView
Savara Inc. (SVRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Is Savara Inc. (YB4P) stock supported by free cash flowDip Buying & Daily Price Action Insights - Newser
Savara (NASDAQ:SVRA) Shares Up 6.8%What's Next? - MarketBeat
Savara (SVRA) Stock Analysis Report | Financials & Insights - Benzinga
Savara (NASDAQ:SVRA) Reaches New 1-Year HighShould You Buy? - MarketBeat
Will Savara Inc. (YB4P) stock boost dividends furtherWeekly Trade Recap & Breakout Confirmation Alerts - Newser
Is Savara Inc. stock trading near support levelsRecession Risk & AI Optimized Trade Strategies - Newser
Is Savara Inc. (YB4P) stock a top pick for value investorsEarnings Recap Summary & High Return Stock Watch Alerts - Newser
Savara (NASDAQ:SVRA) Nasdaq Today Specialized Biotech Direction - Kalkine Media
Savara Inc. ticks higher amid takeover speculation - MSN
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System - BioSpace
Savara receives European patent for PAP treatment device By Investing.com - Investing.com Canada
Why analysts upgrade Savara Inc. stockTrade Volume Summary & Weekly High Return Forecasts - Newser
Savara (SVRA) Climbs 27.8% Ahead of 2 Health Conferences - MSN
Savara to Spotlight Lead Therapy in Fireside Chats at Major Healthcare Conferences - MSN
Savara Inc. (SVRA) Rises Amid Takeover Speculation - GuruFocus
Savara (SVRA) Market Activity Stirred by Acquisition Rumor - GuruFocus
Savara Inc. ticks higher amid takeover speculation (SVRA:NASDAQ) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Savara Inc. (SVRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Savara (NASDAQ:SVRA) Shares Gap DownHere's Why - MarketBeat
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Deliver - PharmiWeb.com
Savara, PARI Granted European Patent Covering Drug-Device Combination - marketscreener.com
Savara (SVRA) Secures European Patent for Drug-Device Combo - GuruFocus
Savara receives European patent for PAP treatment device - Investing.com
Is Savara Inc. (YB4P) stock a top hedge fund pickBull Run & Verified Stock Trade Ideas - Newser
F m Investments LLC Acquires 91,830 Shares of Savara Inc. $SVRA - MarketBeat
10 Small Caps With Big Double-Digit Gains - Insider Monkey
Savara to Resubmit BLA for Rare Lung Disease Treatment as Losses Widen in Q2 - MSN
Savara Stock Surges Amid Positive Financial Developments and Raised Price Target - timothysykes.com
Savara Inc. Sees Price Target Raised Amid Promising Drug Developments - StocksToTrade
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):